Pre-Market Safety Must Balance Statistics With Clinical Discernment – FDA
Executive Summary
The next chapter for drug safety will be to more accurately quantify harm and risk in the pre-market setting, FDA's Office of Biostatistics Director Robert O'Neill said at a recent drug safety conference